DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Budesonide inhalation suspension (Drug); Montelukast Sodium (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Bertil Andersson, Study Director, Affiliation: AstraZeneca

Summary

A one year study comparing the safety and effectiveness of Pulmicort (0. 5mg strength given once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will receive 5mg strength SINGULAR.

Clinical Details

Official title: An Evaluation of the Effectiveness of Pulmicort Respules (Budesonide Inhalation Suspension) Versus SINGULAIR (Montelukast Sodium) in Children 2-8 Years Old With Asthma Requiring Controller Therapy.

Study design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study

Primary outcome: Time to first asthma medication as either step-up PULMICORT RESPULES or oral steroids

Secondary outcome:

Incidence and Severity of Adverse Events

Time to 1st additional asthma medication measured at 12 weeks and 26 weeks

Time to 1st acute severe exacerbation (as measured by the need for oral steroids), measured at 12 weeks, 26 weeks, and 52 weeks

Eligibility

Minimum age: 2 Years. Maximum age: 8 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Aged 2 to 8 at study entry

- At least 3 episodes of wheezing in the previous year that lasted more than 24 hours

and affected sleep or symptoms of mild persistent asthma

- use of b-2 agonist treatment on at least 3 of 7 consecutive days or run in

Exclusion Criteria:

- Severe or unstable asthma

- any significant finding at a physical exam

- an exacerbation of asthma in the 30 days before entering the study that might affect

study results in judgement of the study doctor

Locations and Contacts

Additional Information

Starting date: October 2002
Ending date: September 2005
Last updated: March 21, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008